Zhang G, Huong V T T, Battur B, Zhou J, Zhang H, Liao M, Kawase O, Lee E G, Dautu G, Igarashi M, Nishikawa Y, Xuan X
National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido 080-8555, Japan.
Parasitology. 2007 Sep;134(Pt 10):1339-46. doi: 10.1017/S0031182007002892. Epub 2007 May 17.
SUMMARYThe dense granule antigen 4 (GRA4) is known as an immundominant antigen of Toxoplasma gondii and, therefore, is considered as a vaccine candidate. For further evaluation of its vaccine effect, a recombinant plasmid and vaccinia virus, both expressing GRA4, were constructed, and a heterologous prime-boost vaccination regime was performed in a mouse model. The mice immunized with the heterologous prime-boost vaccination regime showed a high level of specific antibody response against GRA4 and a significantly high level of gamma interferon (IFN-gamma) production and survived completely against a subsequent challenge infection with a lethal dose of T. gondii. In addition, the formation of cysts was inhibited in the mice vaccinated with the heterologous prime-boost vaccination regime. These results demonstrate that the heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, could induce both humoral and cellular immune responses and provide effective protection against lethal acute and chronic T. gondii infections in mice.
致密颗粒抗原4(GRA4)是已知的弓形虫免疫显性抗原,因此被视为一种疫苗候选物。为了进一步评估其疫苗效果,构建了表达GRA4的重组质粒和痘苗病毒,并在小鼠模型中进行了异源初免-加强免疫接种方案。用异源初免-加强免疫接种方案免疫的小鼠对GRA4表现出高水平的特异性抗体反应,γ干扰素(IFN-γ)产生水平显著升高,并在随后用致死剂量的弓形虫进行的攻击感染中完全存活。此外,用异源初免-加强免疫接种方案接种的小鼠中囊肿的形成受到抑制。这些结果表明,使用表达GRA4的DNA和痘苗病毒的异源初免-加强免疫接种方案可诱导体液免疫和细胞免疫反应,并为小鼠抵抗致死性急性和慢性弓形虫感染提供有效保护。